Diseases, Conditions, Syndromes

High sustained response rate for glecaprevir, pibrentasvir in HCV

(HealthDay)—For patients with stage 4 or 5 chronic kidney disease and hepatitis C virus (HCV) infection, 12 weeks of treatment with glecaprevir and pibrentasvir results in a high rate of sustained virologic response, according ...

Diseases, Conditions, Syndromes

Mapping hepatitis in Kenya shows where action is needed

A study of the different kinds of hepatitis in Kenya showed areas where the government can focus its efforts to prevent infections. One of the findings was a surprise – giving adults the Hepatitis vaccination has been ignored. ...

Diseases, Conditions, Syndromes

Mavyret approved for hepatitis C

(HealthDay) —Mavyret (glecaprevir and pibrentasvir) has been approved by the U.S. Food and Drug Administration to treat adults with certain types of chronic hepatitis C virus (HCV).

page 11 from 35